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ABSTRACT
Papillary thyroid carcinoma (PTC) is the most prevalent malignant neoplasia of 
the thyroid gland. A fraction of PTC cases show loss of differentiation and aggressive 
behavior, with radioiodine therapy resistance and metastasis. Although microRNAs 
(miRNAs) emerged as promising molecular markers for PTC, their role in the loss of 
differentiation observed during PTC progression remains to be fully understood. We 
performed the large-scale analysis of miRNA expression during PTC progression in 
BRAFT1799A-transgenic animals (Tg-Braf) and thyroid cancer cell lines and identified 
the marked downregulation of several miRNAs from the region 14q32. Data from 
The Cancer Genome Atlas (TCGA) confirmed the global downregulation of miRNAs 
from the 14q32 region in human PTC. The regulatory network potentially suppressed 
by these miRNAs suggests that key cancer-related biological processes such as cell 
proliferation, adhesion, migration and angiogenesis. Among the downregulated 
miRNAs, we observed that miR-654-3p levels decrease with long-term PTC progression 
in Tg-Braf mice and inversely correlate with EMT. The in vitro restoration of miR-
654-3p decreased cell proliferation and migration and induced reprogramming of 
metastasis-related genes, suggesting a tumor suppressor role for this miRNA. In 
conclusion, we show global downregulation of 14q32-encoded miRNAs in an in vivo 
model of PTC progression. The potential circuitry in which these miRNAs are involved 
suggests that these miRNAs could play a key role in the pathophysiology of PTC and 
therefore be relevant for the development of new therapeutic strategies.
INTRODUCTION
In the last decade, an increasing number of thyroid 
cancer cases has been observed worldwide. More than 
64,300 new cases of thyroid cancer are estimated to be 
diagnosed in 2016, leading to 1,980 deaths [1] in USA. 
The most prevalent subtype is papillary thyroid carcinoma 
(PTC), accounting for 80% of all cases. Although PTCs 
typically confer good prognoses, about 5% of PTC 
cases present as aggressive tumors, with radioiodine 
therapy resistance, lymph node metastatic dissemination 
and poor prognosis [2]. The most prevalent genetic 
alterations in thyroid tumors are BRAFT1799A mutation 
and RET/PTC chromosomal rearrangements, which have 
been extensively explored as prognostic markers and 
therapeutic targets [3–5].
miRNAs are small RNA molecules involved in 
post-transcriptional regulation of gene expression, mainly 
through imperfect base pairing with the 3′ untranslated 
region (UTR) of target messenger RNA (mRNA)[6]. 
Several studies have implicated differential expression of 
miRNAs as a promising molecular marker for aggressive 
and recurrent thyroid cancer [7–11]. Due to a short length 
and imperfect base-pairing, a single miRNA is predicted 
to regulate hundreds of target mRNAs. Conversely, several 
miRNAs can cooperate to regulate a single target. Thus, 
the contribution of multiple deregulated miRNAs to post-
transcriptional regulation in thyroid cancer, particularly 
regarding aggressive PTC, remains poorly understood.
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In this study, we used Tg-Braf mice to assess 
the micro-transcriptome during PTC progression and 
identified downregulation of several miRNAs from the 
14q32 genomic region. This region spans ~850 kb and 
harbors distinct imprinted genes (DLK1, RTL1, MEG3, 
MEG8 and DIO3), C/D small nucleolar RNAs (SNORDs) 
and more than 50 miRNA genes, many described as 
tumor suppressors in different types of cancer [12, 13]. 
The observation that a subset of Temple Syndrome 
(TS) patients, in which the 14q32 region is partially 
or completely deleted, present with increased risk of 
developing differentiated thyroid cancer suggests that 
some of the genes located in this region may modulate 
biological processes crucial for thyroid follicular cell 
transformation [14, 15]. Our in silico analysis highlights 
miRNAs from the 14q32 locus as candidate targets in 
PTC. Furthermore, we show tumor suppressor properties 
for miR-654-3p in vitro, which could open perspectives for 
new therapeutic strategies for PTC.
RESULTS
Global downregulation of miRNAs from the 
14q32 genomic locus in a transgenic mouse 
model of PTC and human PTC samples
To identify differentially expressed miRNAs 
during PTC loss of differentiation, we used a transgenic 
mouse model of PTC [16] that harbors a thyroid-targeted 
BRAFT1799A mutation (Figure 1a). While thyroid 
glands extracted from 5-weeks old mice exhibit classic 
well differentiated PTC, thyroid glands from older 
mice show foci of locally invasive poorly differentiated 
thyroid carcinoma [17]. Large scale analysis revealed 
that several miRNAs from the 14q32 genomic region 
are down-regulated during PTC progression (Figure 
1b). Importantly, the miRNAs miR-495-3p, miR-654-
3p, miR-376a-3p and miR-487b-3p exhibited marked 
downregulation after 5 weeks in contrast to a slight 
reduction of expression observed for most miRNA genes 
from this region. Downregulation of miRNAs from the 
14q32 locus was also observed in thyroid cancer cell 
lines, prominently in BRAFT1799A-mutated BCPAP and 
KTC-2 cells, as compared to the normal thyroid cell line 
N-Thy-ORI (Figure 1b). As shown in Figure 1c, the locus 
14q32 comprises 53 miRNA genes divided in two clusters, 
designated here as “miRNA cluster 1” (the larger cluster) 
and “miRNA cluster 2” (the smaller cluster). This region 
also comprises several copies of C/D small nucleolar RNAs 
(SNORDs) 112, 113 and 114, and the imprinted genes 
DLK1, RTL1, MEG3, MEG8 and DIO3. The TCGA portal 
(https://cancergenome.nih.gov) reveals a single patient 
with homodeletion of the entire 14q32 region without 
any additional information regarding heterozygosity in 
thyroid cancer. The analysis of randomly-chosen miRNAs 
from clusters 1 and 2 (miR-654-3p, mir-369-3p, miR-495, 
miR-370-5p, miR-127-5p and miR-376c-3p) in tumor 
cell lines confirmed their downregulation (Figure 1d). 
Importantly, the reduced expression of miRNAs from the 
14q32 locus could not be due to terminal deletion of the 
3′ end of chromosome 14, as the thyroid cancer cell lines 
expressed increased levels of miR-203a, situated ~3Mb 
downstream of the 14q32 locus.
We then analyzed whether downregulation of 
genes located at the 14q32 genomic region is observed in 
human PTC samples. We downloaded mRNA and miRNA 
expression datasets from 57 PTC samples and matched 
non-tumor thyroid tissue from The Cancer Genome Atlas 
(TCGA) project, and observed the downregulation of 
most miRNAs from the 14q32 genomic region (Figure 
2a). Importantly, this reduction of expression is restricted 
to genes situated between DLK1 and DIO3. As shown in 
Figure 2b, we observed an orchestrated expression pattern 
for these miRNAs across samples, suggesting either the 
existence of a polycystronic primary miRNA transcript or 
regulation of the miRNA cluster by a common mechanism. 
The analysis of miRNA expression of the whole TCGA 
dataset, comprising 437 PTC samples and 59 normal 
thyroid tissue samples, also showed the global miRNAs 
downregulation located at the 14q32 region (Figure 2c).
Post-transcriptional regulatory network of 
miRNAs from the 14q32 region
To understand the role of the miRNAs from the 
DLK1-DIO3 region in PTC pathogenesis, we analyzed 
the post-transcriptional regulatory network potentially 
modulated by these miRNAs in silico. As shown in 
Figure 3a, were selected 28 differentially expressed 
miRNAs from the 14q32 region that give rise to 32 mature 
miRNA species. miRNAs with a low or absent number 
of reads were not considered for analysis. We used the 
miRWalk webtool to search for predicted targets of 
each of the 32 mature miRNAs in the 14q32 region. To 
increase the stringency of target prediction, a minimum 
of seven algorithms were considered as a cutoff for each 
miRNA:mRNA interaction. Four mature miRNAs were 
excluded due to the absence of targets predicted by seven 
or more algorithms. A total of 7,886 genes targeted by 28 
miRNAs were included for Gene Set Enrichment Analysis 
(GSEA). As the miRNAs from 14q32 are downregulated 
in PTC, we compared the list of potential targets with 
RNA-seq V2 data from TCGA and searched for those 
presenting upregulation (>1.25-fold) in PTC samples. The 
resulting list of 1,193 predicted targets was subsequently 
submitted to the DAVID webtool to identify enriched 
biological processes and signaling pathways. Sixty-seven 
GO Terms were enriched among the target genes (P value 
< 0.001; Supplementary Table 2). The most significantly-
enriched biological processes were related to cell adhesion 
and motility, cell proliferation and vascular development 
(Figure 3b). Additionally, by comparing the lists of 
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miRNA targets, we identified a significant enrichment 
for 15 out of the 28 miRNAs, suggesting that most of the 
14q32-encoded miRNAs may cooperate to regulate the 
same biological processes (Figure 3c).
Tumor suppressor properties of miR-654-3p in 
thyroid cell lines
Among the differentially expressed miRNAs from 
the 14q32 region, we observed that miR-654-3p levels 
decrease with long-term PTC progression in Tg-Braf mice 
and inversely correlate with the expression of the EMT 
markers Zeb1, Zeb2, Snai1 and Snai2 (Figure 4a). The 
restoration of miR-654-3p expression using commercial 
mimetic miRNA markedly decreased cell proliferation and 
migration, and increased apoptosis in normal and tumor 
thyroid cell lines (Figure 4b and 4c). Importantly, a cell 
migration assay was performed 24 h after miR-654-3p 
transfection, ensuring that the observed effect was due to 
migration impairment rather than decreased proliferation.
To evaluate the participation of miR-654-3p in PTC 
progression, we analyzed the impact of ectopic expression 
Figure 1: MiRNAs from 14q32 region are down regulated in thyroid cancer cell lines and in murine model of PTC. 
a. Large scale analysis of PTC progression In vivo and in vitro. Panel of thyroid cell lines including normal (N-Thy-ORI), PTC cell line 
bearing RET/PTC1 oncogene (TPC-1), and PTC and ATC cell lines bearing BRAFT1799A oncogene (BCPAP and KTC-2, respectively). 
Expression of miRNAs from transgenic animals in each time point was compared with respective wild-type sample. Expression of miRNAs 
for each thyroid cancer cell line was compared with the normal cell line N-Thy-ORI. b. Downregulation of 14q32-encoded miRNAs in 
Tg-Braf mouse model and thyroid cancer cell lines. Heatmap represents the fold change between each thyroid cancer cell line and normal 
cells (N-Thy-ORI) and between Tg-Braf and Wild-type animals in each time point. c. Schematic representation of DLK1-DIO3 region and 
miRNA clusters in 14q32 chromosome locus. The distances of 5’ and 3’ flanking genes CYP46A1, WARS, WRD25, BEGAIN, PPP2R5C 
and WRD20 are not in scale. d. Validation of miRNAs from 14q32 region by independent qPCR assay. Increased expression of miR-203, 
which is located downstream of DLK1-DIO3, shows absence of terminal deletion of chromosome 14. Small RNA U6B (RNU6B) gene was 
used as endogenous control.
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of miR-654-3p on the expression of several genes involved 
in tumor establishment and progression using a Taqman® 
Human Tumor Metastasis qPCR Array. The miR-654-
3p-transfected cells showed increased expression levels 
of the epithelial cell markers CDH1 and CTNNA1 and 
decreased levels of SNAI2, with no significant changes 
in ZEB1, ZEB2, SNAI1 and VIM levels (Figure 4d). No 
morphological changes were observed through light 
microscopy after transfection of miR-654-3p (data not 
shown). Known tumor suppressor genes were upregulated 
after transfection of mimetic miR-654-3p, including 
CASP8, PTEN, DAPK1, RB1 and the cell cycle regulator 
CDKN2A. Moreover, key genes involved in cell adhesion, 
migration and ECM remodeling were downregulated after 
transfection of mimetic miR-654-3p, such as LAMB1 
and MMP9. Also, decreased levels of HRAS, FGF2, 
Figure 2: Global downregulation of miRNAs from 14q32-encoded genes in PTC. a. Gene expression data from 57 paired 
samples downloaded from TCGA website was used to construct the heatmap. Grey boxes represent null values for sequence read either in 
Normal or Tumor sample. (*) BRAFT1799A mutation; (Fusion) BRAF gene fusion. b. Analysis of 57 paired PTC and normal thyroid tissue 
reveals concordant miRNA expression pattern across samples. Samples with null values either for PTC or normal tissue were replaced by 
the lowest value for the given gene. c. Average expression of miRNAs from DLK1-DIO3 region and flanking genes in 437 PTC samples 
compared with 59 normal thyroid samples. (a) p-value <0.05; (b) p-value <0.01; (c) p-value <0.001.
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Figure 3: miRNAs from 14q32 region potentially modulate cancer-related processes. a. The prediction of miRNA targets 
by at least 7 algorithms was performed using miRWalk webtool. RNA-Seq data was searched for upregulated genes (>1.25 fold) and 
the resulting list was submited to DAVID webtool. b. GO terms enriched among the list of potential targets of 14q32-encoded miRNAs. 
c. miRNAs from DLK1-DIO3 region target common genes. Lower triangular matrix shows the p-value of either Fisher's Exact Test of 
Chi-square (if sample size is too large for the Fisher test). Upper triangular matrix shows the number of targets shared by both miRNAs. 
Diagonal numbers are the total number of targets for a given microRNA.
FGFR4 and IL1B, as well as increased NF1, components 
of MAPK signal transduction, were observed after 
transfection of miR-654-3p. Importantly, restoration of 
miR-654-3p upregulated the expression of the metastasis-
suppressor genes BRMS1, MTSS1, KISS1 and NME1, and 
downregulated the expression of several genes related to 
tumor progression and metastasis, including MTA1, MTA2, 
SERPINE1, SSTR2 and CD44. Altogether, these data 
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suggest that restoration of miR-654-3p could contribute to 
a more differentiated, less aggressive phenotype in PTC.
DISCUSSION
Although the abnormal expression of miRNAs 
has been widely described in well-differentiated 
thyroid cancer, the role of these molecules in PTC 
progression remains unclear. In silico and experimental 
analyses suggest that abnormal miRNA expression 
may participate in key biological processes during 
cancer invasion and dissemination, and can contribute 
to aggressive behavior of PTC [10, 18–20]. Using an 
in vivo mouse model of PTC, we identified marked 
Figure 4: miR-654-3p is downregulated during tumor progression of PTC in vivo and regulates cell proliferation and 
migration of PTC in vitro. a. Thyroid tissue extracted from 5-,12- and 30-weeks old animals (Tg-Braf and WT) was homogenized 
and total RNA extracted was used for cDNA synthesis. snRNA U6 and RPL19 were used for normalization of miR-654-3p and Zeb1 Zeb2, 
Snai1 and Snai2 respectively. b. N-Thy-ORI and TPC-1 cells were transfected or not with miR-654-3p mimetic and after 24, 48, and 72 h, 
cells were trypsinized and counted. The data is representative of two independent experiments performed in triplicates. c. TPC-1, BCPAP 
and KTC-2 cells transfected or not with miR-654-3p mimetic were seeded into the upper compartment of modified Boyden chambers with 
8 μm pore inserts as described in Methods section. Representative images are shown. d. BCPAP cells were transfected with 30nM miR-
654-3p mimetic. After 48 h, total RNA was extracted and used for cDNA synthesis. Tumor progression and metastasis genes were profiled 
using Human Tumor Metastasis qPCR Array (Thermo). GAPDH, HPRT and GUSB genes were used as endogenous control. Values in 
Y axis reflect the log2 fold change expression levels between BCPAP cells transfected miR-654-3p mimetic with those not transfected. 
(EMT) Epithelial-to-mesenchymal transition; (Epi) Epithelial markers; (Mes) Mesenchymal markers; (ECM) Extra-cellular Matrix. (A-D) 
(Tg-Braf) Tg-Braf animals; (WT) wild-type animals; (Mock) cells exposed to the transfection reagent only. Bars represent s.d. *P<0.05; 
**P<0.01; ***P<0,001.
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downregulation of miRNAs from the 14q32 region 
concomitant to loss of differentiation and EMT. PTCs 
generated in Tg-Braf animals recapitulate the intra-
tumor heterogeneity observed in a fraction of PTC 
patients, including loss of differentiation, TGFβ-
driven EMT, tumor-associated macrophages and local 
invasiveness [17]. Riesco-Eizaguirre and colleagues 
have shown that BRAFT1799A mutation induces 
repression of thyroid-differentiation gene NIS through 
the activation of a TGF-β autocrine loop, leading to 
radioiodine resistance and poor prognosis [21]. We 
have shown that miRNAs from 14q32 region target 
EMT-related genes, which could contribute with the 
aggressive phenotype observed in these tumors.
Although the deregulation of select individual 
miRNAs from the 14q32 region has been shown in 
PTC cell lines [22, 23], large scale analysis of miRNA 
expression in vivo combined with data mining of the 
TCGA project allowed us to identify the synchronized 
downregulation of miRNAs limited to the 14q32 region 
spanning from the DLK1 to DIO3 genes, also known as 
the DLK1-DIO3 region. The coordinated downregulation 
of miRNAs from the 14q32 region in PTC is aligned 
with the observation of a large polycistronic transcript 
comprising the largest miRNA cluster in the human 
genome [24, 25].
Several studies have shown downregulation of 
miRNAs from the 14q32 region in different types of 
cancer, such as ovarian, breast and prostate cancer, and 
gastrointestinal stromal tumor, [26–29], with significant 
correlations to poor prognosis and aggressiveness. 
Importantly, a tumor suppressor role has been 
recognized in several of the downregulated miRNAs 
from the 14q32 region through the targeting of key 
oncogenes in glioblastoma, neuroblastoma, metastatic 
lung cancer, hepatic cancer, pituitary adenoma and 
rhabdomyosarcoma [30–34]. For example, restoration of 
miR-370 expression led to downregulation of FOXM1 
in acute myeloid leukemia, promoting cell growth 
arrest and senescence [35]. In contrast, miRNAs from 
the 14q32 region may act as oncogenes as well [36–
38], suggesting that these miRNAs may have different 
biological roles depending on the tissue of origin and 
genetic background.
The mechanisms underlying modulation of this 
region remain to be fully understood. In this study, 
increased expression of miR-203 observed in thyroid 
cancer cell lines excludes the existence of terminal 
deletion of chromosome 14. TCGA data shows 
homodeletion of the 14q32 region in one patient sample, 
however without heterozygosis status. Additionally, 
despite a large number of oncogenic mutations that have 
been recently identified in poorly differentiated (PDTC) 
and anaplastic thyroid carcinomas (ATC), no genetic 
alteration spanning the 14q32 region was observed [39]. 
The relationship between MAPK pathway and the 14q32 
region remains uncertain. Cahill and colleagues have 
shown that human derived BRAFT1799A- and RET/
PTC-bearing thyroid tumor cells, KAT10 and TPC-1 
respectively, express lower levels of 14q32-encoded 
miRNAs miR-323-3p, miR-370-5p, miR-127-3p, miR-
299 and miR-154 [22, 23]. However, the in vitro acute 
transfection of each oncogene into the normal thyroid 
cell line N-Thy-ORI did not show the same level of 
impairment of expression of these miRNAs. This 
observation, combined with the long-term (12 weeks) 
downregulation of 14q32-encoded miRNAs during 
progression of PTC in Tg-Braf mice suggests that other 
mechanisms than the driver oncogene activation may 
play an additional role on the silencing of 14q32 genes. 
Recent studies have shown that epigenetic changes, 
such as DNA methylation and chromatin remodeling 
by lncRNA-mediated mechanisms, may participate in 
regulating the expression of the 14q32-encoded miRNAs 
[28, 40]. Also, imprinting imbalance could lead to the 
differential modulation of paternally and maternally 
expressed genes from the 14q32 region and could 
explain, at least in part, the increased levels of DIO3 
observed in some PTC samples [41, 42]. Altogether, 
these data suggest that multiple mechanisms other 
than genetic mutations or chromosomal loss might be 
involved in the regulation of 14q32-encoded miRNAs 
in thyroid cancer.
Due to the large number of miRNAs present in 
the 14q32 region that are concomitantly deregulated, 
the miRNA:target interaction pattern may lead to a 
complex regulatory network that may include thousands 
of potential targets. Our GSEA (Figure 3) indicates 
that miRNAs from the 14q32 region could contribute 
to tumor progression and metastasis by targeting 
key regulators of biological processes involved in 
tumorigenesis and tumor progression, such as cell 
adhesion and migration, proliferation, hypoxic response 
and wound healing. miR-654-3p, which has been 
described as a tumor suppressor miRNA in prostate 
cancer cell lines [28], is downregulated during PTC 
progression in the Tg-Braf model and in human PTC 
samples. Our functional analysis indicates that miR-654-
3p markedly decreases cell proliferation and increases 
apoptosis, possibly by restoring the expression of key 
tumor suppressor genes. Although no morphological 
changes were observed, transfection of miR-654-3p 
increased the expression of CDH1 and CTNNA1, and 
decreased the expression of SNAI2, which is consistent 
with an “epithelial” genetic program. Importantly, the 
levels of key modulators of tumor progression, such as 
ECM and ECM-remodeling genes, as well as metastasis-
suppressing and -promoting genes, were restored after 
transfection of a miR-654-3p mimetic.
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In conclusion, we have identified the global 
downregulation of miRNAs from 14q32 region in a mouse 
model of PTC progression and in human PTC samples. 
The potential network modulated by these miRNAs may 
contribute to important aspects of cancer development and 
progression, such as cell adhesion, migration, angiogenesis 
and proliferation. Finally, in vitro functional analyses 
highlight tumor suppressor properties for miR-654-3p in 
PTC. Due to the large number of potential key cancer-
related targets, further functional analyses of miRNAs 
from the 14q32 region may be of great interest for the 
development of new therapeutic strategies for thyroid 
cancer.
MATERIALS AND METHODS
Cell lines and animals
The PTC-derived cell line TPC-1, which 
spontaneously harbors RET/PTC1 rearrangement, was 
kindly provided by Dr James A Fagin (Human Oncology 
and Pathogenesis Program, Memorial Sloan-Kettering 
Cancer Center, New York, NY, USA). BCPAP, derived 
from BRAFT1799A-positive PTC was kindly donated 
by Dr Massimo Santoro (Medical School, University 
‘Federico II’ of Naples, Naples, Italy). The ATC-derived 
cell line KTC-2, also harboring BRAFT1799A oncogene 
was kindly provided by Dr. Norisato Mitsutake (Nagasaki 
University Graduate School of Biomedical Sciences, 
Nagasaki, Japan). The origin and genetic background of 
these cell lines has been recently authenticated [43, 44]. 
Immortalized non-tumoral thyroid follicular cells N-Thy-
ORI were purchased from Sigma and maintained in RPMI 
(Invitrogen) supplemented with 10% FBS and 2 mM 
L-glutamine (Invitrogen). TPC-1 and BCPAP cells were 
cultivated as previously described [45]. KTC-2 cells were 
maintained in RPMI supplemented with 5% FBS. All cell 
lines were cultivated with 100 U/ml penicillin, 1μg/ml 
streptomycin and 100μg/ml amphotericin at 37oC and in 
a 5% CO2 atmosphere.
FVB transgenic mice, harboring the thyroid-targeted 
expression of BRAFT1799A oncogene [16] as well as 
their wild-type counterparts were donated by Dr James 
Fagin (Human Oncology and Pathogenesis Program, 
Memorial Sloan-Kettering Cancer Center, New York, NY, 
USA), and FVB WT mice were used as control. Animal 
experimentation was conducted in accordance with 
guidelines from the Ethical Committee of the Institute of 
Biomedical Sciences (n#134/ p93/ b2), University of São 
Paulo, Brazil.
Gene expression analysis
For the large scale analysis of miRNA expression, 
thyroid glands were surgically removed from euthanized 
animals at different time points (1, 5, 12 and 30 weeks) 
and embedded in RNA Later (Ambion). Total RNA 
was phenol-chloroform-extracted using TRIzol reagent 
(Invitrogen) from homogenized thyroid tissue samples 
according to the manufacturer’s instructions. Small RNA 
fraction was purified using miRNeasy kit (Qiagen) and 
integrity was verified using Agilent small RNA chip 
in Agilent Bioanalyzer (Agilent). MiRNA expression 
quantification was performed using miScript II RT kit for 
reverse transcription and murine miScript PCR Arrays 
(Qiagen) for mature miRNA amplification, according to 
manufacturer’s instructions. Data analysis was performed 
using the online software PCR Array Data Analysis 
Web Portal (http://pcrdataanalysis.sabiosciences.com/
mirna/arrayanalysis.php). The melting curve of each 
amplification product was manually checked to assure the 
specificity of the reaction. In order to increase reliability, 
the standard deviation for the Ct values of the 5 genes 
provided as endogenous controls were calculated and the 
endogenous gene with the highest value was discarded.
For quantification of miRNA and mRNA expression 
in vitro, 1x105 cells were seeded into 60 mm dishes. 
Forty-eight hours after transfection of miRNA mimetic, 
total RNA was phenol-chloroform-extracted using TRIzol 
reagent (Invitrogen) according to the manufacturer’s 
instructions. For miRNA expression analysis 10 ng of total 
RNA was reverse transcribed using TaqMan® MicroRNA 
Reverse Transcription kit (Applied Biosystems) according 
to the manufacturer’s instructions. MiRNA expression 
was detected using TaqMan Universal PCR Master 
Mix No AmpErase UNG (Applied Biosystems). For the 
quantification of mRNA expression 2 μg of total RNA was 
reverse transcribed using MMLV Reverse transcription 
kit (Life). RNA U6 small nuclear 2 (RNU6B) and RPL19 
genes were used as endogenous controls for normalization 
of miRNA and mRNA input, respectively. The expression 
of metastasis-related genes was quantified using Human 
Tumor Metastasis Taqman® Array plate (Thermo-
Fischer), according with manufacturer’s instructions. All 
amplification reactions were performed using universal 
cycling conditions in ViiA-7 Real-Time PCR System 
(Applied Biosystems). RT primers part numbers for 
miRNA (Applied Biosystems) and the oligonucleotides 
used for qPCR reaction are shown in Supplementary 
Table 1. The differential gene expression was calculated 
according with Pfafll [46].
Data mining of the Cancer Genome Atlas
miRNA (miRNASeq) and mRNA (RNASeqV2) 
Gene expression, Copy Number Variation (CNV Lowpass 
DNA-Seq) and clinical data were downloaded in “level 
3” format from TCGA web portal (https://cancergenome.
nih.gov). miRNA and mRNA differential expression was 
calculated using Normalized Read count data for each 
individual sample. For miRNA and mRNA expression 
analysis, transcripts were considered not valid when 42 or 
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more (75%) pairs, out of 57 PTC versus matched normal 
tissue, had not valid fold changes. In total, 579 out of 
1,046 miRNAs were excluded and 467 were considered 
valid. Also, mRNA transcripts whose median expression 
were <= 5 reads across all 114 samples (57 PTC and 
paired normal tissue) were excluded (5,142 out of 20,502).
Gene Set Enrichment Analysis
The miRNA-target prediction was performed using 
miRWalk program (http://www.umm.uni-heidelberg.de/
apps/zmf/mirwalk/), accessing a total of 12 algorithms. 
To increase stringency, one interaction was considered 
valid when predicted by TargetScan algorithm and 7 or 
more algorithms. The list of potential targets was then 
compared with RNA-seq dataset downloaded from TCGA. 
Upregulated (> 1.25 fold) mRNA targets were selected and 
submitted to DAVID web tool (https://david.ncifcrf.gov/). 
Biological processes enriched among the target genes 
potentially targeted by miRNAs from region 14q32 were 
identified. The enrichment of common targets between 
each miRNA from 14q32 region was calculated using 
Fisher's Exact Test or Fisher's Exact Test of Chi-square, if 
sample size is too large for the Fisher test.
Transient transfection of miR-654-3p mimetic
Normal and tumor thyroid cells were transfected 
with miR-654-3p miRVana mimic (Life Technologies) at 
concentration of 10-30nM. The concentration of 30nM 
was proved to be more efficient and used for further 
experiments. Transfection was performed 24h after 
seeding using Lipofectamine 2000® (Invitrogen). Cells 
exposed to transfection reagent only were used as control 
and denominated Mock.
Cell proliferation, migration and apoptosis
Cell counting, migration and apoptosis analyses 
were performed as previously described, with 
modifications [45, 47]. Growth curve and apoptosis were 
measured using Guava EasyCyte Mini Flow Cytometer 
(Guava Technologies). Migrating cells were visualized 
after staining with 0.5% Crystal Violet in Ethanol in Nikon 
Eclipse E600 microscope.
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism Software version 5.00 (San Diego, CA, USA). 
After the test for normality using Kolmogrov-Smirnov 
test, samples were compared using non-parametric 
Mann-Whitney test, when they presented non-Gaussian 
distribution, and using Students t test, when they 
p-resented Gaussian distribution. Differences were 
considered significant when P<0.05.
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